Our data demonstrated that Ruxolitinib significantly reduced the percentage of RORγt and IL-17 positive cells, and thus IL-6 might be taken into consideration as a possible therapeutic agent for preventing bone loss during periodontitis. The gene discussed is IL17A; the disease is periodontitis.